# Efficacy and safety of adjunctive acupuncture for depression and motor symptoms in Parkinson’s disease: study protocol for a randomized controlled trial

**Authors:** Kaihao Liao, Jing-Qi Fan, Liangman Xiao, Danxia Gu, Mingda Han, Jingyu Nian, Shunan Wu, Li-Xing Zhuang

PMC · DOI: 10.3389/fpsyt.2026.1760698 · Frontiers in Psychiatry · 2026-02-16

## TL;DR

This study tests if acupuncture can help with depression and motor symptoms in Parkinson's disease patients, and if it affects related biological markers.

## Contribution

The study provides a rigorous trial protocol to evaluate acupuncture as a non-pharmacological treatment for depression in Parkinson's disease.

## Key findings

- The trial will assess changes in depression scores and motor function in Parkinson's patients receiving acupuncture.
- Exploratory analyses will investigate biomarkers like inflammatory cytokines and BDNF to correlate with clinical outcomes.

## Abstract

Depression is one of the most prevalent and disabling non-motor symptoms in Parkinson’s disease (PD), forming a bidirectional relationship with motor dysfunction that worsens quality of life. Pharmacological treatments exhibit limited and inconsistent efficacy, and may lead to adverse interactions. Acupuncture may improve both depressive and motor symptoms by regulating the neuro–immune–endocrine network, but high-quality evidence remains insufficient.

This study aims to evaluate the efficacy and safety of acupuncture as an adjunctive therapy for depression in PD and to explore potential biological correlates of clinical changes using predefined serum biomarkers.

In this single-center, evaluator-blinded, randomized controlled trial, 88 patients with PD and comorbid depression will be randomly assigned to an acupuncture group or a waitlist control group. The primary outcome is the change in the Montgomery–Asberg Depression Rating Scale (MADRS) score. Secondary outcomes include motor function, anxiety, sleep quality, and overall quality of life. Exploratory analyses will assess serum inflammatory cytokines, brain-derived neurotrophic factor (BDNF), and kynurenine/tryptophan (KYN/TRP) ratio.

We hypothesize that adjunctive acupuncture may improve depressive and motor symptoms compared with the control. Exploratory analyses will examine whether clinical changes are associated with changes in relevant biomarkers.

This study will provide rigorous evidence for acupuncture as an adjunctive therapy, offering a non-pharmacological strategy to optimize the comprehensive management of PD and disrupt the bidirectional emotion–motor interplay.

https://www.chictr.org.cn/, identifier ChiCTR2500113443.

## Linked entities

- **Proteins:** BDNF (brain derived neurotrophic factor)
- **Diseases:** Parkinson’s disease (MONDO:0005180), depression (MONDO:0002050)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** emotional and motor impairments (MESH:D000068079), dopaminergic dysfunction (MESH:D009422), functional impairment (MESH:D003072), Movement Disorder (MESH:D009069), rigidity (MESH:D009127), dementia (MESH:D003704), soreness (MESH:D063806), hepatic or renal failure (MESH:D017093), Parkinson (MESH:D010302), bipolar disorder (MESH:D001714), depression (MESH:D003866), neuronal degeneration (MESH:D009410), inflammatory cytokines (MESH:D000080424), MDS (MESH:C000719191), numbness (MESH:D006987), cerebrovascular disease (MESH:D002561), CRF (MESH:C565541), infection (MESH:D007239), cardiovascular disease (MESH:D002318), bradykinesia (MESH:D018476), dopaminergic neuronal injury (MESH:D020196), impaired consciousness (MESH:D003244), death (MESH:D003643), symptoms (MESH:D012816), postural instability (MESH:D054972), systemic diseases (MESH:D034721), arrhythmia (MESH:D001145), bleeding (MESH:D006470), mood or motor symptoms (MESH:D019964), schizophrenia (MESH:D012559), neuroinflammation (MESH:D000090862), Anxiety (MESH:D001007), malignancy (MESH:D009369), alcohol or substance abuse (MESH:D019966), Mental Disorders (MESH:D001523), insomnia (MESH:D007319), neurotoxic (MESH:D020258), PD (MESH:D010300), pain (MESH:D010146), serotonin syndrome (MESH:D020230), hematoma (MESH:D006406), syncope (MESH:D013575), neurodegeneration (MESH:D019636), gastrointestinal symptoms (MESH:D012817), Inflammatory (MESH:D007249)
- **Chemicals:** serotonin (MESH:D012701), alcohol (MESH:D000438), TRP (MESH:D014364), iodine (MESH:D007455), levodopa (MESH:D007980), antiparkinsonian medication (-), quinolinic acid (MESH:D017378), KYN (MESH:D007737), norepinephrine (MESH:D009638)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12951315/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12951315/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12951315/full.md

---
Source: https://tomesphere.com/paper/PMC12951315